Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses

• Published in: bioRxiv
• Main Authors: Walls, Alexandra C, Sprouse, Kaitlin R, Joshi, Anshu, Bowen, John E, Franko, Nicholas, Navarro, Mary Jane, Stewart, Cameron, McCallum, Matthew, Goecker, Erin A, Degli-Angeli, Emily J, Logue, Jenni, Greninger, Alex, Chu, Helen, Veesler, David
• Format: Journal Article Paper
• Language: English
• Published: United States Cold Spring Harbor Laboratory Press 13.12.2021; Cold Spring Harbor Laboratory
• Edition: 1.2
• Subjects: Antibodies; Antigens; Biotechnology; Coronaviruses; COVID-19 vaccines; Immunology; Infections; Mutation; Nanoparticles; Pandemics; Patent applications; Severe acute respiratory syndrome coronavirus 2; Vaccines
• ISSN: 2692-8205; 2692-8205
• DOI: 10.1101/2021.12.08.471707

The SARS-CoV-2 Delta variant is currently responsible for most infections worldwide, including among fully vaccinated individuals. Although these latter infections are associated with milder COVID-19 disease relative to unvaccinated subjects, the specificity and durability of antibody responses elicited by Delta breakthrough cases remain unknown. Here, we demonstrate that breakthrough infections induce serum binding and neutralizing antibody responses that are markedly more potent, durable and resilient to spike mutations observed in variants of concern than those observed in subjects who were infected only or received only two doses of COVID-19 vaccine. However, wee show that Delta breakthrough cases, subjects who were vaccinated after SARS-CoV-2 infection and individuals vaccinated three times (without infection) have serum neutralizing activity of comparable magnitude and breadth indicate that multiple types of exposure or increased number of exposures to SARS-CoV-2 antigen(s) enhance spike-specific antibody responses. Neutralization of the genetically divergent SARS-CoV, however, was moderate with all four cohorts examined, except after four exposures to the SARS-CoV-2 spike, underscoring the importance of developing vaccines eliciting broad sarbecovirus immunity for pandemic preparedness.